Alzamend Neuro Inc

ALZN

Company Profile

  • Business description

    Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

  • Contact

    3480 Peachtree Road NE
    Second Floor Suite 103
    AtlantaGA30326
    USA

    T: +1 844 722-6333

    https://www.alzamend.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 April 2026

    Employees

    7

Stocks News & Analysis

stocks

Our top ASX picks in every sector

These companies are our top choices for investors wanting to boost Aussie exposure.
stocks

Potentially catastrophic ruling for ASX company

We raise our risk and uncertainty rating to reflect the impact of the ruling.
stocks

4 charts on Nvidia’s record $4 trillion market cap

Shares of the semiconductor giant have rocketed 280% over the past two years amid the AI boom.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,875.3060.000.68%
CAC 407,775.8032.37-0.41%
DAX 4024,098.7161.93-0.26%
Dow JONES (US)44,216.87242.78-0.55%
FTSE 1008,951.5846.48-0.52%
HKSE24,590.12386.801.60%
NASDAQ20,772.97132.650.64%
Nikkei 22539,678.02218.400.55%
NZX 50 Index12,689.6310.940.09%
S&P 5006,271.693.130.05%
S&P/ASX 2008,630.3059.900.70%
SSE Composite Index3,505.0014.65-0.42%

Market Movers